CytomX Therapeutics (CTMX) Other Non-Current Assets (2014 - 2026)
CytomX Therapeutics (CTMX) reported Other Non-Current Assets of $31000.0 for Q1 2026, down 49.18% on a YoY basis from $61000.0 in Q1 2025, and down 97.97% quarter-over-quarter from $1.5 million in Q4 2025.
CytomX Therapeutics (CTMX) Other Non-Current Assets (2014 - 2026) Analysis & Trends
CytomX Therapeutics has reported Other Non-Current Assets for 13 years, with the latest figure at $31000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 49.18% year-over-year to $31000.0; the trailing twelve-month figure through Mar 2026 stood at $31000.0 (down 49.18% YoY), and the FY2025 full-year result was $1.5 million, up 48.69% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $31000.0, down from $1.5 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.5 million in Q4 2025, with the low at $27000.0 in Q4 2022.
- Historically, Other Non-Current Assets has averaged $562529.4 across 5 years, with a median of $917000.0 in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets plunged 97.06% — and 2024, when it soared 1137.35%.
- CytomX Therapeutics' Other Non-Current Assets stood at $27000.0 in 2022, then soared by 207.41% to $83000.0 in 2023, then soared by 1137.35% to $1.0 million in 2024, then jumped by 48.69% to $1.5 million in 2025, then slumped by 97.97% to $31000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $31000.0 (Q1 2026), $1.5 million (Q4 2025), and $51000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | CytomX Therapeutics | 520.30 Mn | 173.59 Mn | - | 31,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31,000.00 |
| Dec 31, 2025 | 1.53 Mn |
| Sep 30, 2025 | 51,000.00 |
| Jun 30, 2025 | 56,000.00 |
| Mar 31, 2025 | 61,000.00 |
| Dec 31, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 917,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Dec 31, 2023 | 83,000.00 |
| Sep 30, 2023 | 917,000.00 |
| Jun 30, 2023 | 91,000.00 |
| Mar 31, 2023 | 917,000.00 |
| Dec 31, 2022 | 27,000.00 |
| Sep 30, 2022 | 917,000.00 |
| Jun 30, 2022 | 917,000.00 |
| Mar 31, 2022 | 917,000.00 |
| Dec 31, 2021 | 917,000.00 |
| Sep 30, 2021 | 917,000.00 |
| Jun 30, 2021 | 917,000.00 |